BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22892126)

  • 1. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
    Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
    Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
    Zhang M; Liu M; Xiong M; Gong J; Tan X
    J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria.
    Nishiyama A; Nakagawa T; Kobori H; Nagai Y; Okada N; Konishi Y; Morikawa T; Okumura M; Meda I; Kiyomoto H; Hosomi N; Mori T; Ito S; Imanishi M
    J Hypertens; 2008 Sep; 26(9):1849-59. PubMed ID: 18698221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
    Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
    Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
    Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.
    Miceli I; Burt D; Tarabra E; Camussi G; Perin PC; Gruden G
    Am J Physiol Renal Physiol; 2010 Feb; 298(2):F381-90. PubMed ID: 19906946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
    Wang S; Li Y; Huang YJ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Sep; 27(9):1003-6. PubMed ID: 21906476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
    Wang S; Li Y; Zhao J; Zhang J; Huang Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
    Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
    Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats.
    Cha JJ; Kang YS; Hyun YY; Han SY; Jee YH; Han KH; Han JY; Cha DR
    Life Sci; 2013 Jun; 92(23):1118-24. PubMed ID: 23643633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
    Sofue T; Kiyomoto H; Kobori H; Urushihara M; Nishijima Y; Kaifu K; Hara T; Matsumoto S; Ichimura A; Ohsaki H; Hitomi H; Kawachi H; Hayden MR; Whaley-Connell A; Sowers JR; Ito S; Kohno M; Nishiyama A
    Am J Hypertens; 2012 May; 25(5):604-11. PubMed ID: 22318512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase-2 (MMP-2) and membrane-type 1 MMP (MT1-MMP) affect the remodeling of glomerulosclerosis in diabetic OLETF rats.
    Furuichi K; Hisada Y; Shimizu M; Okumura T; Kitagawa K; Yoshimoto K; Iwata Y; Yokoyama H; Kaneko S; Wada T
    Nephrol Dial Transplant; 2011 Oct; 26(10):3124-31. PubMed ID: 21414971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of renal alterations in obese type 2 diabetic mice by vasohibin-1, a negative feedback regulator of angiogenesis.
    Saito D; Maeshima Y; Nasu T; Yamasaki H; Tanabe K; Sugiyama H; Sonoda H; Sato Y; Makino H
    Am J Physiol Renal Physiol; 2011 Apr; 300(4):F873-86. PubMed ID: 21228103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservations of nephrin and synaptopodin by recombinant hepatocyte growth factor in podocytes for the attenuations of foot process injury and albuminuria in nephritic mice.
    Kato T; Mizuno S; Nakamura T
    Nephrology (Carlton); 2011 Mar; 16(3):310-8. PubMed ID: 21342325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin ameliorates podocyte damage by restoring renal tissue nephrin expression in type 2 diabetic rats.
    Zhai L; Gu J; Yang D; Hu W; Wang W; Ye S
    J Diabetes; 2017 May; 9(5):510-517. PubMed ID: 27248136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
    Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
    Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FK506 ameliorates podocyte injury in type 2 diabetic nephropathy by down-regulating TRPC6 and NFAT expression.
    Ma R; Liu L; Jiang W; Yu Y; Song H
    Int J Clin Exp Pathol; 2015; 8(11):14063-74. PubMed ID: 26823720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.